目的 探究艾司唑仑结合氟哌噻吨美利曲辛对肺癌合并失眠患者睡眠质量的改善效果.方法 便利选取2023年2-12月建瓯市中西医结合医院收治的78例肺癌合并失眠患者为研究对象,采用奇偶数法将其分为对照组(39例,常规方案治疗)和观察组(39例,艾司唑仑联合氟哌噻吨美利曲辛治疗).对比两组患者睡眠质量、夜间睡眠时间、生活质量以及不良反应.结果 治疗前,两组患者匹兹堡睡眠质量指数量表(Pitts-burgh Sleep Quality Index,PSQI)评分对比,差异无统计学意义(P>0.05);治疗后,观察组PSQI评分低于对照组,差异有统计学意义(t=11.052,P<0.05).治疗后,观察组夜间睡眠时间长于对照组,觉醒次数少于对照组,差异有统计学意义(t=12.428、15.052,P均<0.05).观察组不良反应总发生率(2.56%)低于对照组(20.51%),差异有统计学意义(χ2=4.522,P<0.05).治疗前,两组患者生命质量测定量表简表(World Health Organization Quality of Life Scale Brief Form Questionnaire,WHOQOL-BREF)评分对比,差异无统计学意义(P>0.05);治疗后,观察组的WHOQOL-BREF高于对照组,差异有统计学意义(P<0.05).结论 对肺癌合并失眠患者采用艾司唑仑结合氟哌噻吨美利曲辛治疗,可以改善患者的睡眠质量与生存质量,且不良反应较少.
The Effect of Estazolam Combined with Flupentixol and Melitracen in the Treatment of Lung Cancer Patients with Insomnia and Its Influence on Sleep Quality
Objective To explore the effect of estazolam combined with flupentixol and melitracen on sleep quality of patients with lung cancer complicated with insomnia.Methods From February to December 2023,78 patients with lung cancer complicated with insomnia admitted to Jian'ou Hospital of Integrated Traditional Chinese and Western Medicine were conveniently selected as study objects divided into control group(39 cases,routine treatment)and ob-servation group(39 cases,estazolam combined with flupentixol and melitracen treatment)by odd and even number method.The sleep quality,nighttime sleep time,quality of life and adverse reactions were compared between the two groups.Results Before treatment,there was no significant difference in Pittsburgh Sleep Quality Index(PSQI)score between the two groups(P>0.05).After treatment,the PSQI score of the observation group was lower than that of the control group,and the difference was statistically significant(t=11.052,P<0.05).After treatment,the nighttime sleep time of the observation group was longer than that of the control group,and the number of awakenings was less than that of the control group,the differences were statistically significant(t=12.428,15.052,both P<0.05).The total inci-dence of adverse reactions in the observation group(2.56%)was lower than that in the control group(20.51%),and the difference was statistically significant(χ2=4.522,P<0.05).Before treatment,there was no significant difference in the World Health Organization Quality of Life Scale Brief Form Questionnaire(WHOQOL-BREF)score between the two groups(P>0.05).After treatment,the WHOQOL-BREF of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion In the treatment of lung cancer patients with insomnia,the combination of esomeprazole and flupentixol can improve the sleep quality of patients,increase their quality of life,and reduce adverse reactions.
Lung cancerInsomniaEszolamFlupentixol and melitracinSleep qualityQuality of lifeAdverse reactionsNighttime sleep time
NETL
NSTL
万方数据
